We are live on ! Find out more
SGYP

Synergy Pharmaceuticals
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

77 hedge funds and large institutions have $116M invested in Synergy Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 35 increasing their positions, 18 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

94% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 18

84% more call options, than puts

Call options by funds: $381K | Put options by funds: $207K

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

39% more capital inflows, than outflows

Capital inflows: $14.3M | Capital outflows: $10.3M

7% more funds holding

Funds holding: 72 → 77 (+5)

0.89% more ownership

Funds ownership: 27.22% → 28.1% (+0.89%)

Holders
77
Holders Change
+5
Holders Change %
+6.94%
% of All Funds
2.49%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
11
Increased
35
Reduced
18
Closed
6
Calls
$381​K
Puts
$207​K
Net Calls
+$174​K
Net Calls Change
+$441​K

SGYP Hedge Fund Activity: Q3 2013 in Review

77 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals (SGYP) for Q3 2013, worth a combined $116M — up 9.2% from $106M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new SGYP positions and 6 closed out — a net gain of 5 holders — while 35 added to existing stakes and 18 trimmed.

The largest buyer was UBS AM, opening a new position worth an estimated $2.84M. The largest seller was Bridger Management, exiting entirely with an estimated $4.6M sold.

  • 77 institutional investors held Synergy Pharmaceuticals (SGYP) as of Q3 2013, up from 72 in Q2 2013.
  • Funds reported $116M of Synergy Pharmaceuticals stock for Q3 2013, up 9.2% quarter-over-quarter.
  • 11 funds opened new Synergy Pharmaceuticals positions in Q3 2013 and 6 closed out, a net change of +5 holders.
  • The largest Synergy Pharmaceuticals buyer in Q3 2013 was UBS AM, an estimated $2.84M added.
  • The largest Synergy Pharmaceuticals seller in Q3 2013 was Bridger Management, an estimated $4.6M sold.

Based on aggregated 13F filings for Q3 2013.